Chapter 37: Biologic Response Modifier Drugs

The text explains how advances in recombinant DNA and hybridoma technology have enabled the mass production of these complex proteins, facilitating both targeted and indirect therapies. A major focus is placed on Interferons (IFNs), which are categorized into Type I (alpha and beta) and Type II (gamma); these cytokines work by inhibiting viral replication, slowing tumor growth, and regulating immune responses, with specific indications for conditions such as hairy cell leukemia, Multiple Sclerosis (MS), and chronic granulomatous disease. The chapter also details Colony-Stimulating Factors (CSFs), essential in oncology for minimizing myelosuppression and reducing the duration of neutropenia, thus permitting higher chemotherapy dosages. This section differentiates between Erythropoietin-Stimulating Agents (ESAs) like epoetin alfa, which treat anemia but carry black-box warnings for cardiovascular events when hemoglobin is greater than 11 g/dL, and Granulocyte Colony-Stimulating Factors (G-CSF) like filgrastim that boost neutrophil counts. Furthermore, the summary covers Interleukins, specifically Interleukin-2 (aldesleukin), used for metastatic renal cell carcinoma and melanoma, while highlighting the life-threatening risk of Capillary Leak Syndrome, which causes fluid extravasation and multiorgan failure. Newer advancements such as Chimeric Antigen Receptor (CAR) T-cell therapy are introduced, describing the genetic modification of a patient's T cells to target cancer antigens, along with the critical management of Cytokine Release Syndrome (CRS). Finally, the chapter outlines the Clinical Judgment Nursing Process, emphasizing the need to monitor for adverse effects like neuropsychiatric toxicity, hypersensitivity, and infection, ensuring patient safety throughout immunotherapy.